In this case study, AstraZeneca finds that purifying antibodies with Fibro PrismA means they can screen more candidates per week with a simpler equipment set up
Residence time with Fibro technology is measured in seconds, because binding properties do not depend on flow rate. This rapid purification enables high-throughput screening for monoclonal antibody (mAb) candidate drugs and cell lines.
Fibro chromatography enables higher productivity from research, process development to large scale manufacturing. Learn more in the on-demand webinars:
Fibro chromatography is based on electrospun cellulose fibers that enables the combination of high flow rates with high binding capacity. This technology offers new opportunities for flexible, high-productivity purification solutions from process development to manufacturing scale.
